A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Role: Supports fat loss
Full peptide profile All stacksFat Loss 
The GLP-1 Fat Loss Stack
Semaglutide handles the appetite side of fat loss — it mimics GLP-1, the gut hormone that signals satiety to the brain, slows gastric emptying, and reduces cravings. Clinical trials showed 9-17% body weight reduction at therapeutic doses. AOD-9604 targets fat directly — it is the fat-regulating fragment of human growth hormone that stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) without affecting blood sugar or IGF-1. Where semaglutide reduces intake, AOD-9604 accelerates mobilization of stored fat. Together they approach fat loss from both the caloric intake and fat mobilization angles without overlapping mechanisms.
🐾 Griffin Says...
The semaglutide data speaks for itself — it is one of the most studied compounds in obesity research history. AOD-9604 adds targeted fat mobilization on top. The mechanisms do not overlap, which is exactly what you want in a stack. One reduces what goes in, the other helps move what is stored.
Peptides in this stack
A modified fragment of human growth hormone (amino acids 176-191) studied specifically for fat metabolism. Has FDA GRAS status as a food ingredient.
Role: Supports fat loss
Full peptide profileFor research purposes only. Nothing on this page is medical advice or a recommendation to use these compounds. Always consult a qualified professional before making health decisions.
Want to go deeper on these?
Join the community and swap notes with other researchers. 🐾
$9/month or $90/year